Neonatal abstinence syndrome: Historical perspective, current focus, future directions

Preventive Medicine

Volumn 80, Issue , 2015, Pages 12-17

  Jones, Hendrée E ^a,b   Fielder, Andrea ^c  

^a UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^b JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF SOUTH AUSTRALIA   (Australia)

Author keywords

Neonatal abstinence syndrome; Neonatal opioid withdrawal; Opioid use disorder

Indexed keywords

ALCOHOL; BENZODIAZEPINE DERIVATIVE; BUPRENORPHINE; CAFFEINE; CLONIDINE; COCAINE; DIAZEPAM; METHADONE; MORPHINE; OPIATE; PHENOBARBITAL; SEROTONIN UPTAKE INHIBITOR; NARCOTIC ANALGESIC AGENT;

ARTICLE; BIRTH WEIGHT; CLINICAL ASSESSMENT; CLINICAL PROTOCOL; CONCEPT FORMATION; DIAGNOSTIC ACCURACY; DIAGNOSTIC TEST ACCURACY STUDY; DRUG ABUSE; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG EXPOSURE; DRUG WITHDRAWAL; FINNEGAN SCORING SYSTEM; HEALTH STATUS; HEROIN DEPENDENCE; HISTORY; HOSPITALIZATION; HUMAN; MEDICAL INFORMATION; MEDICAL RESEARCH; METHADONE TREATMENT; MONOTHERAPY; MOTHER NAS SCALE; NEONATAL ABSTINENCE SCORING SYSTEM; NEONATAL DRUG WITHDRAWAL SCORING SYSTEM; NEONATAL NARCOTIC WITHDRAWAL INDEX; NEONATAL OPIOID WITHDRAWAL SCALE; NEONATAL WITHDRAWAL INVENTORY; NEWBORN MORTALITY; OPIATE ADDICTION; OPIOID AND BENZODIAZEPINE WITHDRAWAL SCALE; PREGNANCY; PREMATURITY; PRIORITY JOURNAL; PSYCHOMETRY; RATING SCALE; RELIABILITY; SCORING SYSTEM; SENSITIVITY AND SPECIFICITY; SYMPTOM; TREATMENT FAILURE; TREATMENT INDICATION; WITHDRAWAL ASSESSMENT TOOL; WITHDRAWAL SYNDROME; ADULT; FEMALE; INFANT; NEONATAL ABSTINENCE SYNDROME; NEWBORN; OPIATE SUBSTITUTION TREATMENT; PREGNANCY COMPLICATION; PROCEDURES;

ADULT; ANALGESICS, OPIOID; FEMALE; HISTORY, 19TH CENTURY; HISTORY, 20TH CENTURY; HISTORY, 21ST CENTURY; HUMANS; INFANT; INFANT, NEWBORN; METHADONE; NEONATAL ABSTINENCE SYNDROME; OPIATE SUBSTITUTION TREATMENT; PREGNANCY; PREGNANCY COMPLICATIONS;

EID: 84942553731     PISSN: 00917435     EISSN: 10960260     Source Type: Journal    
DOI: 10.1016/j.ypmed.2015.07.017     Document Type: Article

References (68)

1. Abrahams R.R., Kelly S.A., Payne S., Thiessen P.N., Mackintosh J., Janssen P.A. Rooming-in compared with standard care for newborns of mothers using methadone or heroin. Can. Fam. Physician 2007, 53:1722-1730.
2. Abrahams R.R., MacKay-Dunn M.H., Nevmerjitskaia V., MacRae G.S., Payne S.P., Hodgson Z.G. An evaluation of rooming-in among substance-exposed newborns in British Columbia. J. Obstet. Gynaecol. Can. 2010, 32:866-871.
3. Agthe A.G., Kim G.R., Mathias K.B., Hendrix C.W., Chavez-Valdez R., Jansson L., Lewis T.R., Yaster M., Gauda E.B. Clonidine as an adjunct therapy to opioids for neonatal abstinence syndrome: a randomized, controlled trial. Pediatrics 2009, 123:e849-e856.
4. Binder T., Vavrinkova B. Prospective randomised comparative study of the effect of buprenorphine, methadone and heroin on the course of pregnancy, birthweight of newborns, early postpartum adaptation and course of the neonatal abstinence syndrome (NAS) in women followed up in the outpatient department. Neuro Endocrinol. Lett. 2008, 29:80-86.
5. Blinick G., Wallach R.C., Jerez E. Pregnancy in narcotics addicts treated by medical withdrawal. The methadone detoxification program. Am. J. Obstet. Gynecol. 1969, 105:997-1003.
6. Blinick G., Wallach R.C., Jerez E., Ackerman B.D. Drug addiction in pregnancy and the neonate. Am. J. Obstet. Gynecol. 1976, 125:135-142.
7. Case C.L. The pathology and treatment of morphinism. Cal State J. Med. 1905, 3:352-354.
8. Coyle M.G., Ferguson A., Lagasse L., Oh W., Lester B. Diluted tincture of opium (DTO) and phenobarbital versus DTO alone for neonatal opiate withdrawal in term infants. J. Pediatr. 2002, 140:561-564.
9. Desmond M.M., Wilson G.S. Neonatal abstinence syndrome: recognition and diagnosis. Addict. Dis. 1975, 2:113-121.
10. Eyler F.D., Behnke M., Garvan C.W., Woods N.S., Wobie K., Conlon M. Newborn evaluations of toxicity and withdrawal related to prenatal cocaine exposure. Neurotoxicol. Teratol. 2001, 23:399-411.
11. Finnegan L.P., Kaltenbach K. Neonatal abstinence syndrome. Primary Pediatric Care 1992, 1367-1378. Mosby, St. Louis. second ed. R.A. Hoekelman, S.B. Friedman, N.M. Nelson, H.M. Seidel (Eds.).
12. Finnegan L.P., Connaughton J.F., Kron R.E., Emich J.P. Neonatal abstinence syndrome: assessment and management. Addict. Dis. 1975, 2:141-158.
13. Fischer G., Jagsch R., Eder H., Gombas W., Etzersdorfer P., Schmidl-Mohl K., Schatten C., Weninger M., Aschauer H.N. Comparison of methadone and slow-release morphine maintenance in pregnant addicts. Addiction 1999, 94:231-239.
14. Food and Drug Administration Dangerous Mixups Between Opium Tincture and Paregoric. FDA Patient Safety News: Show #27, May 2004 2004.
15. Franck L.S., Naughton I., Winter I. Opioid and benzodiazepine withdrawal symptoms in paediatric intensive care patients. Intensive Crit. Care Nurs. 2004, 20:344-351.
16. Franck L.S., Harris S.K., Soetenga D.J., Amling J.K., Curley M.A. The Withdrawal Assessment Tool-1 (WAT-1): an assessment instrument for monitoring opioid and benzodiazepine withdrawal symptoms in pediatric patients. Pediatr. Crit. Care Med. 2008, 9:573-580.
17. Gaalema D.E., Scott T.L., Heil S.H., Coyle M.G., Kaltenbach K., Badger G.J., Arria A.M., Stine S.M., Martin P.R., et al. Differences in the profile of neonatal abstinence syndrome signs in methadone- versus buprenorphine-exposed neonates. Addiction 2012, 107(Suppl. 1):53-62.
18. Gaalema D.E., Heil S.H., Badger G.J., Metayer J.S., Johnston A.M. Time to initiation of treatment for neonatal abstinence syndrome in neonates exposed in utero to buprenorphine or methadone. Drug Alcohol Depend. 2013, 133:266-269.
19. Goodfriend M.J., Shey I.A., Klein M.D. The effects of maternal narcotic addiction on the newborn. Am. J. Obstet. Gynecol. 1956, 71:29-36.
20. Gordon A.L., Lopatko O.V., Haslam R.R., Stacey H., Pearson V., Woods A., Fisk A., White J.M. Ineffective morphine treatment regimen for the control of neonatal abstinence syndrome in buprenorphine- and methadone-exposed infants. J. Dev. Orig. Health Dis. 2012, 3:262-270.
21. Green M., Suffet F. The neonatal narcotic withdrawal index: a device for the improvement of care in the abstinence syndrome. Am. J. Drug Alcohol Abuse 1981, 8:203-213.
22. Haddad P.M., Pal B.R., Clarke P., Wieck A., Sridhiran S. Neonatal symptoms following maternal paroxetine treatment: serotonin toxicity or paroxetine discontinuation syndrome?. J. Psychopharmacol. 2005, 19:554-557.
23. Happel J.J. Morphinism in its relation to the sexual functions and appetite and its effect on the off-spring of the users of the drug. Med. Surg. Rep. 1892, 68:403-407.
24. Hodgson Z.G., Abrahams R.R. A rooming-in program to mitigate the need to treat for opiate withdrawal in the newborn. J. Obstet. Gynaecol. Can. 2012, 34:475-481.
25. Hudak M.L., Tan R.C. Neonatal drug withdrawal. Pediatrics 2012, 129:e540-e560.
26. Hughes P.H., Rieche O. Heroin epidemics revisited. Epidemiol. Rev. 1995, 17:66-73.
27. Institute of Medicine [U.S.] Committee for the Substance Abuse Coverage Study, Gerstein D.R., Harwood H.J., National Institute on Drug Abuse Treating Drug Problems 1990, National Academy Press, Washington, D.C.
28. Isbister G.K., Dawson A., Whyte I.M., Prior F.H., Clancy C., Smith A.J. Neonatal paroxetine withdrawal syndrome or actually serotonin syndrome?. Arch. Dis. Child. Fetal Neonatal Ed. 2001, 85:F147-F148.
29. Jansson L.M., Velez M., Harrow C. The opioid-exposed newborn: assessment and pharmacologic management. J. Opioid Manag. 2009, 5:47-55.
30. Johnson K., Gerada C., Greenough A. Treatment of neonatal abstinence syndrome. Arch. Dis. Child. Fetal Neonatal Ed. 2003, 88:F2-F5.
31. Jones H.E., Velez M.L., McCaul M.E., Svikis D.S. Special treatment issues for women. Methadone Treatment for Opioid Dependence 1999, 251-280. Johns Hopkins University Press, Baltimore. E.C. Strain, M. Stitzer (Eds.).
32. Jones H.E., Harrow C., O'Grady K.E., Crocetti M., Jansson L.M., Kaltenbach K. Neonatal abstinence scores in opioid-exposed and nonexposed neonates: a blinded comparison. J. Opioid Manag. 2010, 6:409-413.
33. Jones H.E., Kaltenbach K., Heil S.H., Stine S.M., Coyle M.G., Arria A.M., O'Grady K.E., Selby P., Martin P.R., et al. Neonatal abstinence syndrome after methadone or buprenorphine exposure. N. Engl. J. Med. 2010, 363:2320-2331.
34. Jones H.E., Finnegan L.P., Kaltenbach K. Methadone and buprenorphine for the management of opioid dependence in pregnancy. Drugs 2012, 72:747-757.
35. Jones H.E., Heil S.H., Baewert A., Arria A.M., Kaltenbach K., Martin P.R., Coyle M.G., Selby P., Stine S.M., et al. Buprenorphine treatment of opioid-dependent pregnant women: a comprehensive review. Addiction 2012, 107(Suppl. 1):5-27.
36. Jones H.E., Chisolm M.S., Jansson L.M., Terplan M. Naltrexone in the treatment of opioid-dependent pregnant women: the case for a considered and measured approach to research. Addiction 2013, 108:233-247.
37. Joseph H., Stancliff S., Langrod J. Methadone maintenance treatment (MMT): a review of historical and clinical issues. Mt Sinai J. Med. 2000, 67:347-364.
38. Kandall S.R., Gartner L.M. Late presentation of drug withdrawal symptoms in newborns. Am. J. Dis. Child. 1974, 127:58-61.
39. Kraft W.K., Dysart K., Greenspan J.S., Gibson E., Kaltenbach K., Ehrlich M.E. Revised dose schema of sublingual buprenorphine in the treatment of the neonatal opioid abstinence syndrome. Addiction 2011, 106:574-580.
40. Laine K., Heikkinen T., Ekblad U., Kero P. Effects of exposure to selective serotonin reuptake inhibitors during pregnancy on serotonergic symptoms in newborns and cord blood monoamine and prolactin concentrations. Arch. Gen. Psychiatry 2003, 60:720-726.
41. Lee T.S. Slow-release morphine was not more effective than methadone in reducing neonatal abstinence syndrome. West. J. Med. 2000, 172:26.
42. Levinson-Castiel R., Merlob P., Linder N., Sirota L., Klinger G. Neonatal abstinence syndrome after in utero exposure to selective serotonin reuptake inhibitors in term infants. Arch. Pediatr. Adolesc. Med. 2006, 160:173-176.
43. Lipsitz P.J. A proposed narcotic withdrawal score for use with newborn infants. A pragmatic evaluation of its efficacy. Clin. Pediatr. (Phila) 1975, 14:592-594.
44. Maguire D., Cline G.J., Parnell L., Tai C.Y. Validation of the Finnegan neonatal abstinence syndrome tool-short form. Adv. Neonatal. Care 2013, 13:430-437.
45. Martin C.E., Longinaker N., Terplan M. Recent trends in treatment admissions for prescription opioid abuse during pregnancy. J. Subst. Abuse Treat. 2015, 48:37-42.
46. McElhatton P.R. The effects of benzodiazepine use during pregnancy and lactation. Reprod. Toxicol. 1994, 8:461-475.
47. Menninger-Lerchenthal E. Die morphinkrankheit der neugeborenen morphinistischer mütter [The morphine disease of the newborn in morphine-using mothers]. Monastscr f Kinderh 1934, 60:182-193.
48. O'Grady M.J., Hopewell J., White M.J. Management of neonatal abstinence syndrome: a national survey and review of practice. Arch. Dis. Child. Fetal Neonatal Ed. 2009, 94:F249-F252.
49. Ogunyemi D., Hernandez-Loera G.E. The impact of antenatal cocaine use on maternal characteristics and neonatal outcomes. J. Matern. Fetal Neonatal Med. 2004, 15:253-259.
50. Osborn D.A., Jeffery H.E., Cole M.J. Opiate treatment for opiate withdrawal in newborn infants. Cochrane Database Syst. Rev. 2010, CD002059.
51. Osborn D.A., Jeffery H.E., Cole M.J. Sedatives for opiate withdrawal in newborn infants. Cochrane Database Syst. Rev. 2010, CD002053.
52. Ostrea E.M., Chavez C.J., Strauss M.E. A study of factors that influence the severity of neonatal narcotic withdrawal. J. Pediatr. 1976, 88:642-645.
53. Patrick S.W., Schumacher R.E., Benneyworth B.D., Krans E.E., McAllister J.M., Davis M.M. Neonatal abstinence syndrome and associated health care expenditures: United States, 2000-2009. JAMA 2012, 307:1934-1940.
54. Perlstein M.A. Congenital morphinism; a rare cause of convulsions in the newborn. J. Am. Med. Assoc. 1947, 135:633.
55. Pettey G.E. Congenital morphinism, with report of cases: general treatment of morphinism. South. Med. J. 1912, 65:95-98. (32:37-63).
56. Pierog S., Chandavasu O., Wexler I. Withdrawal symptoms in infants with the fetal alcohol syndrome. J. Pediatr. 1977, 90:630-633.
57. Rementeria J.L., Bhatt K. Withdrawal symptoms in neonates from intrauterine exposure to diazepam. J. Pediatr. 1977, 90:123-126.
58. Rosenthal T., Patrick S.W., Krug D.C. Congenital neonatal narcotics addiction: a natural history. Am. J. Public Health Nations Health 1964, 54:1252-1262.
59. Sanz E.J., De-las-Cuevas C., Kiuru A., Bate A., Edwards R. Selective serotonin reuptake inhibitors in pregnant women and neonatal withdrawal syndrome: a database analysis. Lancet 2005, 365:482-487.
60. Sarkar S., Donn S.M. Management of neonatal abstinence syndrome in neonatal intensive care units: a national survey. J. Perinatol. 2006, 26:15-17.
61. Siu A., Robinson C.A. Neonatal abstinence syndrome: essentials for the practitioner. J. Pediatr. Pharmacol. Ther. 2014, 19:147-155.
62. Thaithumyanon P., Limpongsanurak S., Praisuwanna P., Punnahitanon S. Perinatal effects of amphetamine and heroin use during pregnancy on the mother and infant. J. Med. Assoc. Thail. 2005, 88:1506-1513.
63. United Nations Office on Drugs and Crime Heroin. Bull. Narc. 1953, 5:62-73.
64. Velez M., Jansson L.M. The opioid dependent mother and newborn dyad: non-pharmacologic care. J. Addict. Med. 2008, 2:113-120.
65. Vermont Oxford Network iNICQ 2015: A Universal Training Solution Improving Outcomes for Infants and Families Affected by Neonatal Abstinence Syndrome (NAS) 2014.
66. Wainer H. Estimating coefficients in linear models: it don't make no nevermind. Psychol. Bull. 1976, 83:2213-2217.
67. Zahorodny W., Rom C., Whitney W., Giddens S., Samuel M., Maichuk G., Marshall R. The neonatal withdrawal inventory: a simplified score of newborn withdrawal. J. Dev. Behav. Pediatr. 1998, 19:89-93.
68. Zimmermann-Baer U., Notzli U., Rentsch K., Bucher H.U. Finnegan neonatal abstinence scoring system: normal values for first 3days and weeks 5-6 in non-addicted infants. Addiction 2010, 105:524-528.